New drug shows promise for irreversible hair loss
NCT ID NCT05076006
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tested a new drug (PF-06700841) in 51 adults with cicatricial alopecia, a type of hair loss that destroys hair follicles and leaves scars. The main goals were to check the drug's safety and see how it affects certain genes in the skin and blood. Researchers hope this will lead to better treatments for this hard-to-treat condition.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CICATRICIAL ALOPECIA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Icahn School of Medicine at Mount Sinai
New York, New York, 10029, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.